Overview
This study will prospectively enroll a total of 1000 patients (200 per year) simple hyperplasia/complex hyperplasia (SH/CH) without atypia. All subjects will receive education for exercise and weight control and be randomized 1:1 to with or without metformin intervention. At the end of this 3-year project, an interim analysis will be performed. Since long-term follow-up is intended, therefore for the 4th to 6th year a new grant support will be looked for. The long-term occurrence of endometrial cancer (up to15 years) data will be acquired from national cancer registry, which permission is addressed in the informed sent.
Description
The first year: (1) the cumulative progression rate of SH/CH without atypia to endometrial cancer (EC) of the 1989-2011 cohort will be investigated by linking with national health databases from Health and Welfare Data Science Center (HWDC); (2) Prospectively enroll 200 patients with SH/CH without atypia and deliver education for exercise and weight control and collect the related biospecimens and data; (3) 1:1 randomized to with or without metformin intervention.
The 2nd year: (1) analyze the whole genome sequencing (WGS) data of those progressed and non-progressed ; (2) analyze the metabolomic data in relation to exercise and weight control data.
The 3rd year: (1) validate microRNA (miR) panel in tissues and sera selected by CMRPG3G1511-3; (2) analyze data of MiR panel, degree of exercise/weight control, clinical lab data, and demographic data on EC progression rate; (3) Incremental predicting proficiency of the model including metabolomics data and WGS.
Eligibility
Inclusion Criteria:
- Women aged ≧ 20 years
- Histological diagnosis of SH/CH without atypia
- Not taking Metformin for diabetes mellitus currently
- Adequate kidney function
- Provided informed consent within 3 months of diagnosis
- No previous history of breast cancer with tamoxifen use
- Willing to be followed for 5 years
Exclusion Criteria:
- Atypical hyperplasia or EC found within 3 months after enrollment
- History or concurrent gynecologic cancers or cervical intraepithelial neoplasia
- Pregnancy test positive
- History of intolerance to Metformin
- Family history of HNPCC